Moving beyond anti-vascular endothelial growth factor therapy in ovarian cancer

Journal of Clinical Oncology

Volumn 30, Issue 4, 2012, Pages 345-347

  Sood, Anil K ^a   Coleman, Robert L ^a   Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; BEVACIZUMAB; CARBOPLATIN; GEMCITABINE; PACLITAXEL; PLACEBO; TREBANANIB; TYROSINE KINASE RECEPTOR; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

CANCER CHEMOTHERAPY; EDITORIAL; HUMAN; NEOVASCULARIZATION (PATHOLOGY); OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOPOIETINS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; OVARIAN NEOPLASMS; RECEPTOR, TIE-2;

EID: 84856693516     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.8413     Document Type: Editorial

References (22)

1. Yap TA, Carden CP, Kaye SB: Beyond chemotherapy: Targeted therapies in ovarian cancer. Nat Rev Cancer 9:167-181, 2009
2. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006 (Pubitemid 43048949)
3. Katsumata N, Yasuda M, Takahashi F, et al: Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: A phase 3, open-label, randomised controlled trial. Lancet 374:1331-1338, 2009
4. Huang L, Cronin KA, Johnson KA, et al: Improved survival time: What can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer? Cancer 112:2289-2300, 2008 (Pubitemid 351628641)
5. Cannistra SA, Matulonis UA, Penson RT, et al: Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25:5180-5186, 2007 (Pubitemid 350232248)
6. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic Oncology Group Study 25:5165-5171, 2007
7. Burger RA, et al: Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study. J Clin Oncol 28, 2010 (suppl; abstr LBA1)
8. Kristensen G, Perren T, Qian W, et al: Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol 29, 2011 (suppl; abstr LBA5006)
9. Aghajanian C, Finkler NJ, Rutherford DA, et al: OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). J Clin Oncol 29, 2011 (suppl; abstr LBA5007)
10. Cohn DE, Kim KH, Resnick KE, et al: At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 29:1247-1251, 2011
11. Lu C, Han HD, Mangala LS, et al: Regulation of tumor angiogenesis by EZH2. Cancer Cell 18:185-197, 2010
12. Spannuth WA, Sood AK, Coleman RL: Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 5:194-204, 2008 (Pubitemid 351493679)
13. Huang H, Bhat A, Woodnutt G, et al: Targeting the ANGPT - TIE2 pathway in malignancy. Nat Rev Cancer 10:575-585, 2010
14. Zhang L, Yang N, Park JW, et al: Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 63:3403-3412, 2003 (Pubitemid 36735901)
15. Chae SS, Kamoun WS, Farrar CT, et al: Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 16:3618-3627, 2010
16. Karlan BY, Oza AM, Richardson GE, et al: Randomized, double-blind, placebocontrolled phase 2 study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol 30:362-371, 2012
17. Cannistra SA: Phase II trials in Journal of Clinical Oncology. J Clin Oncol 27:3073-3076, 2009
18. Stone RL, Sood AK, Coleman RL: Collateral damage: Toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol 11:465-475, 2010
19. Azad NS, Posadas EM, Kwitkowski VE, et al: Combination therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709-3714, 2008
20. Koh YJ, Kim HZ, Hwang SI, et al: Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell 18:171-184, 2010
21. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 4:423-436, 2004 (Pubitemid 38745528)
22. Burstein HJ: Bevacizumab for advanced breast cancer: All tied up with a RIBBON. J Clin Oncol 29:1232-1235, 2011